A. Bilsland

发表

Transcriptional repression of telomerase RNA gene expression by c-Jun-NH2-kinase and Sp1/Sp3.

Walter Kolch, Katrina Stevenson, W. Kolch, 2006, Cancer research.

Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors.

A. Schätzlein, A. Bilsland, W. Keith, 2005, Cancer research.

Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition

Meenakshi Malhotra, Alan Bilsland, Amr Amin, 2015, Seminars in cancer biology.

Identification of a Selective G1-Phase Benzimidazolone Inhibitor by a Senescence-Targeted Virtual Screen Using Artificial Neural Networks12

Masashi Narita, Angelo Pugliese, Alan E. Bilsland, 2015, Neoplasia.

Investigating Various Thresholds as Immunohistochemistry Cutoffs for Observer Agreement

Victoria Brown, N. Jamieson, F. Duthie, 2017, Applied immunohistochemistry & molecular morphology : AIMM.

A ‘synthetic-sickness’ screen for senescence re-engagement targets in mutant cancer backgrounds

Ceri M. Wiggins, M. Narita, C. Torrance, 2017, PLoS genetics.

Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.

Gloria S. Huang, A. Azmi, Shijun Mi, 2015, Seminars in cancer biology.

A mutation in a functional Sp 1 binding site of the telomerase RNA gene ( hTERC ) promoter in a patient with Paroxysmal Nocturnal Haemoglobinuria

T. Vulliamy, Jiangqin Zhao, A. Bilsland, 2015 .

A mutation in a functional Sp1 binding site of the telomerase RNA gene (hTERC) promoter in a patient with Paroxysmal Nocturnal Haemoglobinuria

T. Vulliamy, Jiangqin Zhao, A. Bilsland, 2004, BMC blood disorders.

Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954

R. Glasspool, Jiangqin Zhao, A. Bilsland, 2001, Oncogene.

Plasma N-acetyl-glucosaminidase in advanced gastro-intestinal adenocarcinoma correlates with age, stage and outcome.

K. Rudolph, A. Bilsland, W. Keith, 2015, Future oncology.

Mining Cellular Senescence for Drug Targets

A. Bilsland, W. Keith, 2010 .

Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives

A. Bilsland, C. Cairney, W. Nicol Keith, 2011, Journal of cellular and molecular medicine.

A Novel Pyrazolopyrimidine Ligand of Human PGK1 and Stress Sensor DJ1 Modulates the Shelterin Complex and Telomere Length Regulation

A. Turnbull, A. Bilsland, Katrina Stevenson, 2019, Neoplasia.

Drug Insight: cancer cell immortality—telomerase as a target for novel cancer gene therapies

A. Bilsland, W. Keith, T. Evans, 2004, Nature Clinical Practice Oncology.

Fragment‐based drug discovery—the importance of high‐quality molecule libraries

J. Bower, A. Bilsland, M. Bon, 2022, Molecular oncology.

Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery

A. Bilsland, M. Bon, K. McAulay, 2022, Pharmaceuticals.

MicroRNA and senescence: the senectome, integration and distributed control.

A. Bilsland, W. Keith, J. Revie, 2013, Critical reviews in oncogenesis.

Tissue invasion and metastasis: Molecular, biological and clinical perspectives.

A. Azmi, M. Ciriolo, A. Georgakilas, 2015, Seminars in cancer biology.

Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Mark A Feitelson, Alan Bilsland, Amr Amin, 2015, Seminars in cancer biology.

Broad targeting of angiogenesis for cancer prevention and therapy

A. Azmi, W. Rathmell, D. Ribatti, 2015, Seminars in cancer biology.

Virotherapy: cancer gene therapy at last?

A. Bilsland, T. Evans, P. Spiliopoulou, 2016, F1000Research.

Cancer prevention and therapy through the modulation of the tumor microenvironment.

A. Azmi, D. Felsher, R. Whelan, 2015, Seminars in cancer biology.

Immune evasion in cancer: Mechanistic basis and therapeutic strategies.

A. Azmi, G. Pawelec, E. Ryan, 2015, Seminars in cancer biology.

Broad targeting of resistance to apoptosis in cancer

Carmela Fimognari, Alan Bilsland, Amr Amin, 2015, Seminars in cancer biology.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Gloria S. Huang, Rob J. Kulathinal, C. Smythe, 2015, Seminars in cancer biology.

A matrisome RNA signature from early-pregnancy mouse mammary fibroblasts predicts distant metastasis-free breast cancer survival in humans

Joanna S Morris, T. Stein, A. Bilsland, 2021, Breast cancer research : BCR.

A multi-targeted approach to suppress tumor-promoting inflammation.

A. Azmi, L. Ricciardiello, A. Bishayee, 2015, Seminars in cancer biology.

Therapeutic targeting of replicative immortality

A. Azmi, P. Yaswen, G. Firestone, 2015, Seminars in cancer biology.

Dynamic Telomerase Gene Suppression via Network Effects of GSK3 Inhibition

Alan E. Bilsland, Katrina Stevenson, Jon Roffey, 2009, PloS one.

Response to ‘Validating a gene expression signature proposed to differentiate liposarcomas that use different telomere maintenance mechanisms’

N. Zaffaroni, A. Bilsland, W. Keith, 2012, Oncogene.

A gene expression signature classifying telomerase and ALT immortalisation reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT

Nedime Serakinci, Alan Bilsland, Claire J. Cairney, 2009, Oncogene.

Targeting Telomerase: Therapeutic Options for Cancer Treatment

Alan Bilsland, A. Bilsland, W. Keith, 2008 .

Telomerase-directed molecular therapeutics

R. Glasspool, A. Bilsland, W. Keith, 2002, Expert Reviews in Molecular Medicine.

Mathematical Model of a Telomerase Transcriptional Regulatory Network Developed by Cell-Based Screening: Analysis of Inhibitor Effects and Telomerase Expression Mechanisms

Yu Liu, Alan E. Bilsland, Katrina Stevenson, 2014, PLoS Comput. Biol..

Cancer cell senescence: a new frontier in drug development.

M. Narita, C. Torrance, D. Bennett, 2012, Drug discovery today.

Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy.

A. Bilsland, W. Keith, Alan E Bilsland, 2005, Neoplasia.

Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase

I. Ganly, A. Bilsland, W. Keith, 2003, Oncogene.

Activation of telomerase rna gene promoter activity by NF-Y, Sp1, and the retinoblastoma protein and repression by Sp3.

R. Glasspool, A. Bilsland, W. Keith, 2000, Neoplasia.

Involvement of NF‐Y and Sp1 binding sequences in basal transcription of the human telomerase RNA gene

Jiangqin Zhao, A. Bilsland, W. Keith, 2003, FEBS letters.

Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses.

G. Vassaux, A. Bilsland, W. Keith, 2007, Cancer research.

Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms

M Ashcroft, M. Ashcroft, A. Bilsland, 2006, Oncogene.

Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma

Alan Bilsland, Jon Roffey, N. Jamieson, 2010, BMC Genomics.

TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression.

Alan Bilsland, N. Zaffaroni, A. Bilsland, 2010, Neoplasia.

Automated Generation of Novel Fragments Using Screening Data, a Dual SMILES Autoencoder, Transfer Learning and Syntax Correction

Angelo Pugliese, Alan E. Bilsland, Kirsten McAulay, 2021, J. Chem. Inf. Model..

MDM2 negatively regulates the human telomerase RNA gene promoter

Jiangqin Zhao, Alan Bilsland, Jiangqin Zhao, 2005, BMC Cancer.

SFRP1 Expression is Inversely Associated With Metastasis Formation in Canine Mammary Tumours

R. Klopfleisch, T. Stein, A. Bilsland, 2023, Journal of Mammary Gland Biology and Neoplasia.

Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition

A. Azmi, S. Prakash, P. Tran, 2015, Seminars in cancer biology.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Gloria S. Huang, Rob J. Kulathinal, C. Smythe, 2015, Seminars in Cancer Biology.

Immune evasion in cancer: Mechanistic basis and therapeutic strategies.

A. Azmi, G. Pawelec, E. Ryan, 2015, Seminars in cancer biology.

Implementation of an AI-assisted fragment-generator in an open-source platform

J. Bower, A. Bilsland, A. Pugliese, 2022, RSC medicinal chemistry.